About the Authors
- Chaoying Hu
-
Affiliation Phase I Clinical Research Unit, Shanghai Xuhui Central Hospital, Shanghai, China
- Debra Tompson
-
* E-mail: yliu@shxh-centerlab.com (YL); debra.j.tompson@gsk.com (DT)
Affiliation Clinical Pharmacology Modeling and Simulation, GSK Medicines Research Centre, Stevenage, United Kingdom
- Mindy Magee
-
Affiliation Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
- Qian Chen
-
Affiliation Phase I Clinical Research Unit, Shanghai Xuhui Central Hospital, Shanghai, China
- Yan Mei Liu
-
Affiliation Phase I Clinical Research Unit, Shanghai Xuhui Central Hospital, Shanghai, China
- Wenjing Zhu
-
Affiliation China Medicine Development, GlaxoSmithKline (China) R&D Company Limited, Shanghai, China
- Hongxin Zhao
-
Affiliation China Medicine Development, GlaxoSmithKline (China) R&D Company Limited, Shanghai, China
- Annette S. Gross
-
Affiliation Ethnopharmacology, GlaxoSmithKline, Sydney, Australia
- Yun Liu
-
* E-mail: yliu@shxh-centerlab.com (YL); debra.j.tompson@gsk.com (DT)
Affiliation Phase I Clinical Research Unit, Shanghai Xuhui Central Hospital, Shanghai, China
Competing Interests
DT, MM, WZ and AG are GlaxoSmithKline employees and own GSK stock. HZ is a GSK employee. CH, QC, YML and YL have no conflicts of interests to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: CH QC YML WZ HZ YL. Performed the experiments: CH QC YML YL. Analyzed the data: DT WZ HZ. Contributed reagents/materials/analysis tools: DT MM WZ HZ AG. Wrote the paper: DT MM WZ HZ AG. Principal author of the manuscript: DT. Critical review and approval the final version of manuscript: CH DT MM QC YML WZ HZ AG YL.